LYSMD1 Inhibitors
LYSMD1 inhibitors are a class of chemical compounds that target and regulate the function of the LYSMD1 protein, which is a member of the LysM domain-containing proteins. LYSMD1, like other proteins in this family, is characterized by the presence of the LysM domain, a conserved structural motif that mediates binding to specific carbohydrate ligands such as peptidoglycans. This protein is involved in various molecular processes, particularly in the recognition and interaction with components of the cell wall. The inhibitors of LYSMD1 interfere with the protein's ability to engage in these interactions, thereby affecting downstream signaling pathways. Given its role in fundamental molecular recognition processes, LYSMD1 inhibition can modulate certain cellular activities, particularly those related to cell wall interactions and carbohydrate metabolism.
Chemically, LYSMD1 inhibitors can vary significantly in structure, but they often feature motifs that mimic or block the natural ligands of the LysM domain, thereby competitively inhibiting the binding process. These compounds are designed to either directly bind to the LysM domain or indirectly affect its structure through allosteric modulation. This leads to alterations in protein conformation and activity, reducing the LYSMD1-mediated binding affinity for its natural ligands. Such inhibition can lead to broader changes in cell signaling, as the disruption of LYSMD1 activity can affect multiple pathways associated with cell wall recognition and remodeling. The specificity of these inhibitors for the LysM domain makes them valuable tools for probing the fundamental biological roles of LYSMD1 in non-therapeutic research settings.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor which by inhibiting PI3K can decrease AKT phosphorylation and activity, leading to reduced downstream signaling that may be necessary for LYSMD1 function in processes such as vesicular trafficking. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another PI3K inhibitor that prevents phosphorylation of AKT. With AKT activity reduced, cellular processes dependent on PI3K signaling, potentially including those involving LYSMD1, are inhibited. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor which can inhibit the mTORC1 complex, a downstream effector of PI3K/AKT signaling. LYSMD1, which may interact with components regulated by mTORC1, would have diminished functional activity due to reduced mTORC1 signaling. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $56.00 $169.00 | 8 | |
PP242 is a selective mTOR kinase inhibitor that targets both mTORC1 and mTORC2 complexes. This inhibition can suppress the protein synthesis and other cellular events that LYSMD1 might be involved in due to its putative role in lysosomal function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is a p38 MAP kinase inhibitor. By inhibiting p38 MAP kinase, it can suppress the cellular responses to stress or cytokines that LYSMD1 may mediate as part of its functional role in the cell. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a MEK inhibitor that can prevent the activation of the MAPK/ERK pathway. The functional activity of LYSMD1, if reliant on MAPK signaling for processes such as protein sorting, would be inhibited by this compound. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another MEK1/2 inhibitor that blocks the MAPK/ERK pathway, potentially leading to the functional inhibition of LYSMD1 by limiting signaling required for its role in lysosomal function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK pathway. Inhibition of JNK signaling can lead to reduced cellular responses that LYSMD1 may be involved in, such as stress response or apoptosis. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW5074 is a c-Raf kinase inhibitor that can disrupt Raf/MEK/ERK signaling. As this pathway is involved in various cellular responses, LYSMD1 function could be impaired due to reduced signaling required for its activity. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine specifically inhibits the AKT signaling pathway, which would lead to a reduction in cellular processes that rely on AKT function, potentially including those mediated by LYSMD1. | ||||||